Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data

Standing toe-to-toe with giants is nothing to sniff at, but bagging an outright advantage is something else: Just ask Eli Lilly's Taltz, which notched a head-to-head victory against AbbVie's behemoth Humira in psoriatic arthritis. Now, Taltz is doubling up on that win—and hoping doctors will pay attention.